Matthew D. Galsky, MD, Director of Genitourinary Medical Oncology, Tisch Cancer Institute, contextualizes the HCRN GU 16-257 study as a potential game-changer for bladder sparing in patients with MIBC.
HCRN GU 16-257: Neoadjuvant Therapy for Patients With MIBC
By Matthew Galsky, MD - Last Updated: February 24, 2023Post Tags:ASCO GU 2023-Bladder Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.